Skip To Content

ACD/Labs Blog

Daria Thorp
President and CEO, Daria Thorp, reflects on the past year and how the emerging technology of Generative AI and Machine Learning (ML) application in drug discovery and development has inspired companies to look for further industrial applications.

Andrew Anderson
A new year is historically a time for reflection. In 2022, ACD/Labs has been in the scientific software industry for 28 years. In this blog post, Andrew Anderson reflects on three key topics have come up repeatedly in conversations with customers in 2022 that are notable for our work ahead.

Richard Lee
Coding can take scientists from participants to owners of their data. More and more it is becoming clear that every organization needs to employ workers with data science skills. As more scientists become data scientists, the move towards digitalized data will accelerate.

Sanji Bhal
The pharmaceutical industry has renewed its interest in HTE these last few years. Leaders see it as a way to get medicines to patients faster, but they’re also attracted by the sheer quantity of data generated in parallel experiments. How and where should HTE be set up for maximum success? Read this blog for questions that should be considered.

Richard Lee
Richard Lee discusses the global trend around the development of machine learning (ML) and artificial intelligence (AI) capabilities. As utilization of ML/AI continues to grow, R&D organizations will likely continue to focus on how to normalize data into a format that can be fed into a ML/AI framework.

Sanji Bhal
Andrew Anderson recently shared his insight on workflow automation trends in a Pharma Manufacturing article. He emphasizes taking a quality-first approach throughout the automation, digitalization, and analysis processes to truly realize the benefits of Industry 4.0. Here are some of the highlights.